Athersys

Athersys EBIT Growth

Delisted·Oct 1, 2026

The Year-over-Year EBIT Growth of Athersys (ATHXQ) as of Nov 20, 2026 is 11.54 %. In the previous year, Year-over-Year EBIT Growth was -11.14 % — a change of -203.62% (higher).

EBIT Growth

11.54 %

YoY

-203.62%

Last updated:

Year-over-Year EBIT Growth of Athersys is 2022 11.54 % . Year-over-Year EBIT Growth of Athersys was 2021 -11.14 % . It decreases by -203.62% higher compared to the previous year.

The Athersys EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2015
40.81 USD
Jan 1, 2016
8.50 USD
Jan 1, 2017
-111.84 USD
Jan 1, 2018
22.87 USD
Jan 1, 2019
-77.20 USD
Jan 1, 2020
-72.20 USD
Jan 1, 2021
-11.14 USD
Jan 1, 2022
11.54 USD
The Athersys EBIT Growth history
YEAREBIT GrowthYoY
11.54 %-203.62%
-11.14 %-84.57%
-72.20 %-6.48%
-77.20 %-437.62%
22.87 %-120.45%
-111.84 %-1,415.26%
8.50 %-79.17%
40.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Year-over-Year EBIT Growth of Athersys is 11.54 % in 2022.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Athersys since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Athersys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Athersys

All Key Metrics — Athersys